Biomark Diagnostics (Biomark Diagnostics) Scaled Net Operating Assets

: 0.34 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biomark Diagnostics's operating assets for the quarter that ended in Dec. 2023 was $0.77 Mil. Biomark Diagnostics's operating liabilities for the quarter that ended in Dec. 2023 was $0.62 Mil. Biomark Diagnostics's Total Assets for the quarter that ended in Sep. 2023 was $0.47 Mil. Therefore, Biomark Diagnostics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.34.

Biomark Diagnostics Scaled Net Operating Assets Historical Data

The historical data trend for Biomark Diagnostics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-23.18

-28.73

-1.46

0.03

-0.25

Biomark Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.09	-0.45	-0.82	-1.09	0.34

Competitive Comparison

For the Diagnostics & Research subindustry, Biomark Diagnostics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomark Diagnostics Scaled Net Operating Assets Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Scaled Net Operating Assets falls into.

Biomark Diagnostics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biomark Diagnostics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Mar. 2023 )
=	(Operating Assets (A: Mar. 2023 )	-	Operating Liabilities (A: Mar. 2023 ))	/	Total Assets (A: Mar. 2022 )
=	(0.482	-	0.773)	/	1.163
=	-0.25

where

	Operating Assets		(A: Mar. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	0.535	-	0.053
=	0.482

	Operating Liabilities		(A: Mar. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.375	-	0.159	-	0.443
=	0.773

Biomark Diagnostics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Sep. 2023 )
=	(0.773	-	0.615)	/	0.467
=	0.34

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.006	-	0.233
=	0.773

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.423	-	0.408	-	0.4
=	0.615

Biomark Diagnostics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomark Diagnostics (Biomark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

BUX:Canada

Address

130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2

Website

https://www.biomarkdiagnostics.com

Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines